Vaccinex Inc. (VCNX) Share Price Today, Stock Analysis, Annual Report | Value Research Vaccinex Inc. (VCNX) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, share holding, financial report of US stocks.
  • Price Change
  • Market Capitalisation market-capitalisation-info $27 Mln

  • 12 Month Earnings monthly-earning $-10 Mln
  • Price to Earnings price-to-earning --

Vaccinex Inc. (VCNX) Share Price

$0.15

As on 22-Sep-2023 16:00 EDT

up-down-arrow $0.014.95%

  • Prev Close info

    $0.15

  • Day's Openinfo

    $0.15

  • Today's Highinfo

    $0.16

  • Today's Lowinfo

    $0.13

  • Today's Volumeinfo

    287,368

Please wait...

Vaccinex Inc. (VCNX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vaccinex (VCNX)
-75.81 -31.53 -59.66 -76.55 -69.53 -54.77 --
S&P BSE Sensex
8.49 1.22 3.91 11.02 20.17 12.37 12.54
#
-- -- -- -- -- -- --
As on 22-Sep-2023  |  #As on
2022
2021
2020
2019
Vaccinex (VCNX)
-38.46 -49.76 -57.32 33.07
S&P BSE Sensex
4.44 21.99 15.75 14.38
S&P BSE Sensex
4.44 21.99 15.75 14.38

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Vaccinex Inc. (VCNX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Vaccinex Inc. (VCNX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Co-Founder, CEO, Pres & Director

        Dr. Maurice Zauderer Ph.D.

        Chief Financial Officer

        Mr. Scott E. Royer C.F.A., M.B.A.

        Headquarters

        Rochester, NY

        FAQs for Vaccinex Inc. (VCNX)

        The total asset value of Vaccinex Inc. (VCNX) stood at $ 7 Mln as on 31-Mar-23

        The share price of Vaccinex Inc. (VCNX) is $0.154800 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Vaccinex Inc. (VCNX) has given a return of -69.53% in the last 3 years.

        Vaccinex Inc. (VCNX) has a market capitalisation of $ 27 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Vaccinex Inc. (VCNX) is 5.53 times as on 02-Jun-2023, a 1.18% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Vaccinex Inc. (VCNX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Vaccinex Inc. (VCNX) and enter the required number of quantities and click on buy to purchase the shares of Vaccinex Inc. (VCNX).

        Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

        The CEO & director of Dr. Maurice Zauderer Ph.D.. is Vaccinex Inc. (VCNX), and CFO & Sr. VP is Mr. Scott E. Royer C.F.A., M.B.A..

        The promoters of Vaccinex Inc. (VCNX) have pledged 0% of the total equity as on Mar-23.

        Vaccinex Inc. (VCNX) Ratios
        Return on equity(%)
        -459.92
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.03
        Dividend yield(%)
        0

        No, TTM profit after tax of Vaccinex Inc. (VCNX) was $-10 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $27.38 Mln
        • Revenue (TTM)revenue-information $0.65 Mln
        • Earnings (TTM) earning-information $-10.14 Mln
        • Cash date-information $3.32 Mln
        • Total Debt info $0.43 Mln
        • Insider's Holding 11.88%
        • Liquidity liquidity High
        • 52 Week range week-range $0.13 - 0.82
        • Shares outstanding share-outstanding 65,286,000
        • 7 Years Aggregate:

          CFO: $-170.12 Mln

          EBITDA: $-158.39 Mln

          Net Profit: $-165.26 Mln

        About The Company

        • IPO Date 09-Aug-2018
        • Co-Founder, CEO, Pres & Director Dr. Maurice Zauderer Ph.D.
        • Chief Financial Officer Mr. Scott E. Royer C.F.A., M.B.A.
        • Listing key-listing NASDAQ: VCNX
        • Country United States
        • Headquarters headquarters Rochester, NY
        • Website website https://www.vaccinex.com
        • Business

          Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a...  humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon